A comparison of the effectiveness of rosuvastatin, atorvastatin and simvastatin in achieving target lipid levels (according to the PROFILE-I registry)

Сравнение эффективности применения розувастатина, аторвастатина и симвастатина в достижении целевых уровней общего холестерина и липопротеидов низкой плотности (по данным регистра ПРОФИЛЬ-I)
Oleg V Gaisenok 1 2 3
More Detail
1 FSI United Hospital with Outpatient department, Moscow, Russia
2 Research Center of Medical forecasting and analysis, Moscow, Russia
3 National Research Сenter of preventive medicine, Moscow, Russia
J CLIN MED KAZ, Volume 4, Issue 46, pp. 20-25. https://doi.org/10.23950/1812-2892-JCMK-00526
OPEN ACCESS 5108 Views 2841 Downloads
Download Full Text (PDF)

ABSTRACT

The aim of the study: was to evaluate the effectiveness of lipid-lowering therapy, depending on the choice of statin in patients with cardiovascular disease in a cohort study.
Methods: Data analysis was performed in the Profile-I registry patients. The results of the examination of 148 patients were selected for the final analysis on the basis of the presence of indications for prescribing statins, the availability of data on the choice of statin and the availability of results of lipid spectrum from 274 registry patients.
Results: The values ​​of total cholesterol and LDL-С were significantly lower in the rosuvastatin group than in the atorvastatin and simvastatin groups (respectively 4.3, 4.7 and 4.6 mmol/l, p = 0.03;2.36, 2.98, and 2.66 mmol/l, p = 0.01).
Conclusion: the achievement of more optimal levels of lipid spectrum turned out to be dependent on the choice of statin in this study in favor of rosuvastatin.
Keywords: target lipid levels, lipid-lowering therapy, rosuvastatin, atorvastatin, simvastatin

CITATION

Gaisenok OV. A comparison of the effectiveness of rosuvastatin, atorvastatin and simvastatin in achieving target lipid levels (according to the PROFILE-I registry). Journal of Clinical Medicine of Kazakhstan. 2017;4(46):20-5. https://doi.org/10.23950/1812-2892-JCMK-00526

REFERENCES

  • ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal (2011) 32, 1769–1818.
  • Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Eng J Med. 1998; 339: 1349-57.
  • Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the cholesterol and recurrent events (CARE) study. Circulation. 1999; 99: 216-23.
  • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high–risk individuals: a randomised placebo–controlled trial. Lancet. 2002 Jul 6;360(9326):7–22.
  • West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high risk groups and comparison with other cardiovascular intervention trials. Lancet. 1996; 348: 1339-42.
  • Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998; 279:1615–1622.
  • Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower–than–average cholesterol concentrations, in the Anglo–Scandinavian cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT–LLA): A multicentre randomized controlled trial. Lancet. 2003; 361: 1149–1158.
  • Susekov AV, ZubarevaM.Yu., Deev AD, et al. The main results of the Moscow Statin Survey (MSS). Serdtse. 2006; 6: 324-328 [In Russ].
  • Nissen SE, Tuzcu EM, Schoenhagen P, et al. (REVERSAL Investigators). Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 9 (291): 1071–80.
  • Nissen SE, Nicholls SJ, Sipahy I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006; 295 (13): 1556–65.
  • Crouse JR III, Raichlen JS, Riley WA. Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis The METEOR Trial. JAMA 2007; 297: 1344–53.
  • Ridker PM, Danielson E, Fonseca FAH, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. April 4, 2009; 373: 1175–82.
  • Waters D. Comparison of Aggressive Lipid Lowering with Atorvastatin vs. Revascularization Treatments (AVERT) and Conventional Care for the Reduction of Ischemic Events in Patients with Stable Coronary Artery Disease. Cardiovasc Rev Rep. 21 (1):26-31, 2000.
  • Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study - a randomized controlled trial. JAMA 2001; 285: 1711-8.
  • Amarenco P, Bogousslavsky J, Amarenco P et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.
  • The SPARCL Investigators. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL). Cerebrovasc Dis 2003; 16: 389-95.
  • Banegas JR, López-García E, Dallongeville J, Guallar E, Halcox JP, Borghi C, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011 Sep;32(17):2143- 52. doi: 10.1093/eurheartj/ehr080. Epub 2011 Apr 6. 
  • Bener A, Dogan M, Barakat L, Al-Hamaq AO. Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients. Indian J Pharmacol. 2014 Jan-Feb;46(1):88-93. doi: 10.4103/0253-7613.125184. PMID: 24550591 PMCID: PMC3912814
  • Tran YB, Frial T, Miller PS. Statin’s cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins. Can J Clin Pharmacol. 2007 Summer;14(2):e205-14. Epub 2007 Jun 5. PMID: 17556788
  • Bener A, Dogan M, Barakat L, Al-Hamaq AO. Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome. J Prim Care Community Health. 2014 Jul;5(3):180-7. doi: 10.1177/2150131914520991. Epub 2014 Feb 11.
  • Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006 Jan 16;97(2A):33A41A. Epub 2005 Dec 1. Review. PMID: 16442935
  • McGuire TR, Kalil AC, Dobesh PP, Klepser DG, Olsen KM. Anti-inflammatory effects of rosuvastatin in healthy subjects: a prospective longitudinal study. Curr Pharm Des. 2014;20(7):1156-60. PMID: 24467235
  • Sexton TR, Wallace EL, Macaulay TE, Charnigo RJ, Evangelista V, Campbell CL, et al. The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. J Thromb Thrombolysis. 2015 Feb;39(2):186-95. doi: 10.1007/ s11239-014-1142-x. PMID: 25307674
  • Stender S, Schuster H, Barter P, Watkins C, Kallend D; MERCURY I Study Group. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab. 2005 Jul;7(4):430-8. PMID: 15955130 DOI: 10.1111/j.1463-1326.2004.00450.x
  • Statins - HMG-CoA Reductase Inhibitors – Сomparative properties / http://www.globalrph.com/ statins_comparisons.htm